STERIS has pulled back over 2026 even as it pushes ahead with large investments in surgical safety and chemistry production. This raises a simple valuation question for you as a shareholder or prospective buyer: Are the cash flows of this healthcare sterilization and consumables group strong and durable enough to support where the stock trades today?
- The share price is down 11.2% year to date, which puts the current tag under pressure to earn its way through future cash generation rather than recent momentum.
- The planned US$2.1b acquisition of Xodus Medical and the separate US$600m chemistry buildout can reshape growth prospects and margins, while also adding meaningful debt and shifting the timing of cash flows.
- If you'd rather focus on earnings, this one's for you. See what STERIS's 26.9x P/E says about the price.
The stock's next move may depend on whether those planned cash flows, after funding this expansion, line up with the intrinsic value suggested by a Discounted Cash Flow (DCF) view.
If you want a reference point for STERIS and its cash flow story, compare it with companies in the solid balance sheet and fundamentals stocks screener (25 results).
Does STERIS Look Fairly Valued on Cash Flow?
The Discounted Cash Flow model looks at the cash STERIS could return to shareholders over time and then adjusts it back to today’s dollars. In this view, the business is treated as a steady cash generator rather than a high volatility story that hinges on a single year.
Steris produced about $886.9 million of free cash flow over the latest twelve months, and the DCF framework assumes that these cash flows keep growing at modest single digit rates rather than exploding higher or shrinking away. That supports an estimated intrinsic value that sits broadly in line with the current share price of $221.97. The planned US$2.1b Xodus Medical acquisition, financed mainly with debt, is a big swing in this context because it pulls forward investment while the cash benefits arrive later. This helps explain why the market price roughly matches what the DCF cash flow stream supports. Find out what STERIS could be worth using our Discounted Cash Flow (DCF) estimate.
The STERIS Narrative: What Would Justify Today's Price?
Narratives on Simply Wall St extend this valuation puzzle for STERIS into a clear set of "if this, then that" futures, spelling out what would need to happen to growth, profitability and earnings for the stock to be worth materially more or less than it is today on the market. Where a single DCF figure or ratio gives you one number, Narratives unpack the business path that number rests on so you can watch how real world results compare over time, and they sit on the Community page for STERIS' stock.
One of the top community narratives on STERIS: 16% undervalued
"Continued mix shift toward recurring chemistries and services, which now account for roughly 80% of STERIS revenue, can add stability…"
Discover why this Narrative puts STERIS at 16% undervalued.
Before deciding what STERIS is worth, look at who is steering it
Cash flows tell you what STERIS might produce, but the executives who set priorities and the way they are rewarded can heavily influence how that potential is used or squandered. See who runs STERIS and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com